Aigen Investment Management LP Invests $1.21 Million in AbbVie Inc. (NYSE:ABBV)
In the quarter of investing activities* Aigen Investment Management LP purchased 6* thousand shares of Abbvie Inc.s stock on the New York Stock Exchange (ABB. Free Report) as reported in their latest disclosure to the Securities & Exchange Commission.* The investment firm estimated the value of this acquisition at, around $1* million.
Several hedge funds and institutional investors have recently. Sold shares of the company Abbvie as of the second quarter this year. Fairway Wealth LLC acquired a stake in Abbvie worth $26k during the 2nd quarter. Ridgewood Investments LLC also bought into Abbvie during the quarter with a stake valued at approximately $27k. Quest Partners LLC saw an increase in their stake, in Abbvie by 414percent during the second quarter and now holds 212 shares valued at $36k after adding an additional 207 shares to their portfolio. Marquette Asset Management LLC purchased shares of Abbvie during the third quarter for around $39k in value and Burkett Financial Services LLC increased its stake, in Abbvie by 61.% in the same period as they now hold 216 shares worth $43k after acquiring an additional 82 shares recently; Institutional investors collectively hold about 70.% of the companys stock.
A number of stock market analysts have released evaluations regarding ABB shares recently. Wells Fargo & Company increased their projected price for Abbvie shares from 200 to 205 dollars. Assigned the company an "overweight" rating in a report dated Friday the 26th of July. Cantor Fitzgerald reaffirmed an "rating and set a target price of 200 dollars, for Abbvie shares in a report dated Monday the 5th of August. Bank of America raised their projected price for Abbvie from $185 to $195. Assigned a "neutral" rating, in a research report released on Friday the 18th of October.Piper Sandler increased their target price for Abbvie from$196 to$209. Rated the stock as "overweight" in a research note given on Friday the 23rd of August. Guggenheim recently increased their price target for AbbVie shares from $212 to $221. Recommended a "buy." This update was shared in a report on Wednesday 6th November with implications for the stocks performance. Three equity analysts rated the stock as a hold while fifteen gave it a buy rating and one even went far as issuing a strong buy recommendation, for the companys stock. MarketBeat data indicates that the company holds a Moderate Buy" rating and an average target price of approximately$204.06.
Check out the recent research report, about Abbvie.
Abbvies stock began trading at $171 on Wednesday morning with its moving averages standing at $194 for the term and $180 for the long term periods while its highest peak in the last year was over $207 and the lowest drop was around $136 per share. The companys financial health is reflected in its debt, to equity ratio of 9;64 alongside a ratio of 0;65 and a quick ratio of 0;71 to support its operations and growth strategy. The companys market value stands at a $302. 36 Billion, with a price to earnings ratio of 59. 41 And a PEG ratio of 2. 44 While maintaining a beta of 0. 63.
The company also recently announced a dividend that is scheduled to be paid on Friday 14th February next year. Shareholders who are recorded as owners of the stock by Wednesday 15th January will receive a dividend payment of$ 164 per share. The ex dividend date for this payment is also Wednesday January. This dividend increase marks an uptick, from Abbvies quarterly dividend of$ 155. This translates to an annualized dividend of$656. A dividend yield of3.83 %. As of now Abbvie has a payout ratio of227.78 %.
AbbVIe Inc is involved in the discovery and global distribution of products through research and development processes, for the market. The company provides a range of medications including Humira for conditions like autoimmune and intestinal Behçets diseases and pyoderma gangrenosum. They also offer Skyrizi for treating moderate to plaque psoriasis and psoriatic disease along with Crohns disease. Additionally available are Rinvoq to address psoriatic arthritis among other conditions such, as atopic dermatitis and ulcerative colitis.
This breaking news update was created using narrative technology and financial information sourced from MarketBeat to deliver timely and precise reporting to readers in a quick manner with oversight, from MarketBeats editorial staff before being shared for public consumption. For any inquiries or feedback regarding this news update please reach out to contact[at]marketbeat[dot]com.
Before you delve into Abbvies details
MarketBeat monitors the recommendations of regarded research analysts from Wall Street and the stocks they suggest to their customers daily uncovering five stocks that top analysts are discreetly advising their clients to invest in before the wider market becomes aware... Interestingly Abbvie was not, among those recommended stocks.
Analysts currently rate Abbvie as a "Moderate Buy ". Top rated analysts suggest that these five stocks might be better investment options.
Shandor Brenner is an American journalist recognized for his sharp and insightful reporting on social and political issues. His work is known for its depth, integrity, and the ability to highlight critical societal concerns.
